Biotech axes 129 R&D jobs to focus on immunology research.
Biotechnology firm ZymoGenetics of Seattle, Washington, is cutting 129 research and development positions in cancer research. Susan Specht, spokeswoman for the company, says that ZymoGenetics will now concentrate on immunology. “All oncology research projects have been cancelled,” she says. She adds that some R&D positions in cancer research will be transferred to immunology research but could not specify how many. The company, which now employs 349, expects to save US$30 million a year.
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
ZymoGenetics cuts back. Nature 459, 285 (2009). https://doi.org/10.1038/nj7244-285e
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7244-285e